<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00221338</url>
  </required_header>
  <id_info>
    <org_study_id>H5636-26795-01</org_study_id>
    <nct_id>NCT00221338</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Gabapentin to Decrease Postoperative Delirium and Pain</brief_title>
  <official_title>Clinical Trial of Gabapentin to Decrease Postoperative Delirium and Pain in Surgical Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a double blind, placebo-controlled study of patients ≥65 years of age undergoing&#xD;
      surgery of the spine, hips and knees replacement at the University of California, San&#xD;
      Francisco (UCSF) Medical Center. Intraoperative anesthetic and postoperative pain management&#xD;
      will be standardized. Patients will be randomized to receive either placebo or gabapentin&#xD;
      preoperatively, and continued postoperatively until discharge. Intraoperative anesthetic and&#xD;
      other postoperative pain management strategies will be standardized. Postoperative delirium&#xD;
      will be measured using structured interviews. Cognitive function will be measured using a&#xD;
      battery of neurocognitive tests pre- and post-operatively. Using an intention to treat&#xD;
      strategy, we, the researchers at UCSF, will compare the incidence of postoperative delirium&#xD;
      and cognitive dysfunction, the amount of postoperative pain, and narcotic requirements&#xD;
      between the two groups. The primary outcome will be postoperative delirium. Secondary&#xD;
      outcomes will be postoperative pain and opioids use, and length of hospital stay, and&#xD;
      cognitive dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative delirium is a common condition, occurring in 10-70% of surgical patients after&#xD;
      major surgery. To date, few studies have examined events in the postoperative period as&#xD;
      contributing factors to postoperative delirium. We recently completed a study in over 500&#xD;
      geriatric surgical patients to examine whether the mode of postoperative analgesia delivery,&#xD;
      medication types, and the severity of postoperative pain may impact the occurrence of&#xD;
      postoperative delirium. In this study, 46% of patients developed postoperative delirium on&#xD;
      either the first or second postoperative day. By multivariate logistic regression, variables&#xD;
      which had independent association with postoperative delirium included age ≥80 years,&#xD;
      moderate to severe preoperative resting pain, and increased level of resting pain&#xD;
      postoperatively in comparison with preoperative baseline. When the analysis was focused on&#xD;
      patients who used Patient Controlled Analgesia (PCA) alone for postoperative pain control,&#xD;
      the amount of narcotic used (hydromorphone) was significantly higher in those with&#xD;
      postoperative delirium as compared to those without, suggesting that inadequate pain control&#xD;
      and/or the central effects of opioids may be associated with postoperative delirium. Since&#xD;
      increasing the doses of opioids in the elderly patients will likely lead to unwanted side&#xD;
      effects such as respiratory depression, the addition of a non-opioid agent may result in a&#xD;
      narcotic-sparing effect, and also reducing pain postoperatively.&#xD;
&#xD;
      Gabapentin is a structural analog of gamma-amino butyric acid, and has been used as an&#xD;
      anti-convulsant and anti-nociceptive drug. It is not metabolized in humans (therefore no&#xD;
      hepatic enzyme induction), and is eliminated from the body by renal clearance. In animal&#xD;
      studies, gabapentin has been demonstrated to be effective in reducing both allodynia and&#xD;
      hyperalgesia, and may have selective effect on the nociceptive process involved in central&#xD;
      sensitization. Gabapentin has been successfully used in the treatment of neuropathic pain and&#xD;
      other painful conditions. Recently, there is substantial evidence to suggest that gabapentin&#xD;
      also may be useful in the treatment of postoperative pain. To date, there have been nine&#xD;
      randomized clinical trials of gabapentin versus placebo including a total of over 700&#xD;
      patients. Taken together, these studies reported that gabapentin given perioperatively&#xD;
      significantly reduced postoperative analgesic requirements, and had minimum side effects. The&#xD;
      only reported significant side effects in these trials were mild sedation in two studies. In&#xD;
      patients with epilepsy, gabapentin can be introduced at therapeutic doses, and presents no&#xD;
      safety or serious side effect issues. Since gabapentin has negligible protein binding, it has&#xD;
      no interactions with other medications. It is recommended that metabolic and laboratory&#xD;
      monitoring is not necessary, and excellent cognitive profile is evident. At UCSF, gabapentin&#xD;
      has been used safely in a relatively large number of patients on an empiric bases in the&#xD;
      postoperative period, typically in surgical patients with substantial chronic pain, and more&#xD;
      recently, in patients who have undergone spinal surgery as an adjuvant agent to narcotics to&#xD;
      relieve postoperative radicular pain (personal communication with Peter Koo, Clinical&#xD;
      Pharmacist at UCSF). Typically, patients are started on gabapentin 300 mg po TID on the first&#xD;
      day, rapidly escalating to 600 mg TID on the second day, and finally to 900 mg TID the third&#xD;
      day until discharge. The UCSF experience suggests that gabapentin is well tolerated with&#xD;
      minimal side effects.&#xD;
&#xD;
      Hypothesis&#xD;
&#xD;
      We hypothesize that intensive pain management postoperatively using an adjuvant agent,&#xD;
      gabapentin, will lead to a decrease in the amount of postoperative pain experienced, thereby&#xD;
      resulting in a decrease in the incidence of postoperative delirium in older patients&#xD;
      undergoing noncardiac surgery.&#xD;
&#xD;
      Our specific aims were to: 1. Assess whether the administration of gabapentin was associated&#xD;
      with decreased occurrence of delirium, 2. Determine the extent to which gabapentin-associated&#xD;
      reductions in pain and/or opiate use reduced the occurrence of delirium, and 3. Determine&#xD;
      whether the administration of gabapentin was associated with shorter hospital stays. We&#xD;
      hypothesized that intensive pain management postoperatively using an adjuvant agent,&#xD;
      gabapentin, would lead to a decrease in the amount of opioids received, a decrease in&#xD;
      postoperative pain experienced, thereby resulting in a decrease in the incidence of&#xD;
      postoperative delirium.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Postoperative Delirium by Study Group</measure>
    <time_frame>postoperative days 1, 2 and 3</time_frame>
    <description>Number of subjects who developed postoperative delirium, as measured by the Confusion Assessment Method, a validated tool for assessing delirium based on DSM-III-R, on any of the first three postoperative days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Postoperative Opioid Doses Across Study Follow up Period</measure>
    <time_frame>Study follow up period: postoperative days 1, 2 and 3</time_frame>
    <description>Postoperative intravenous opioid doses converted to morphine equivalents. Median derived from total opioid doses on first, second and third postoperative days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>Typically within the first week after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Pain Score - Postoperative Day 1</measure>
    <time_frame>Postoperative day 1</time_frame>
    <description>Postoperative pain as measured by Visual Analog Pain scale (0=no pain, 10=worst pain imaginable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Pain Score - Postoperative Day 2</measure>
    <time_frame>Postoperative day 2</time_frame>
    <description>Postoperative pain as measured by Visual Analog Pain scale (0=no pain, 10=worst pain imaginable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Pain Score - Postoperative Day 3</measure>
    <time_frame>Postoperative day 3</time_frame>
    <description>Postoperative pain as measured by Visual Analog Pain scale (0=no pain, 10=worst pain imaginable).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">750</enrollment>
  <condition>Postoperative Delirium</condition>
  <condition>Postoperative Pain</condition>
  <condition>Opioid Use</condition>
  <condition>Hospital Length of Stay</condition>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double blind, placebo controlled</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Double blind</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days</description>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>gabapentin versus placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female ≥65 years of age undergoing surgery involving the spine, hip or knee&#xD;
             replacement.&#xD;
&#xD;
          -  English speaking.&#xD;
&#xD;
          -  Anticipated to stay in the hospital for at least 48 hours.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who take gabapentin preoperatively, or have known sensitivity to the drug, or&#xD;
             those unable to be randomized to receive gabapentin.&#xD;
&#xD;
          -  Subjects who are unable to provide informed consent.&#xD;
&#xD;
          -  Patients with a history of narcotic tolerance.&#xD;
&#xD;
          -  Patients with planned two stage spinal procedures (anterior-posterior spinal fusion to&#xD;
             be done on two separate days).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacqueline M Leung, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco, CA, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Leung JM, Sands LP, Chen N, Ames C, Berven S, Bozic K, Burch S, Chou D, Covinsky K, Deviren V, Kinjo S, Kramer JH, Ries M, Tay B, Vail T, Weinstein P, Chang S, Meckler G, Newman S, Tsai T, Voss V, Youngblom E; Perioperative Medicine Research Group. Perioperative Gabapentin Does Not Reduce Postoperative Delirium in Older Surgical Patients: A Randomized Clinical Trial. Anesthesiology. 2017 Oct;127(4):633-644. doi: 10.1097/ALN.0000000000001804.</citation>
    <PMID>28727581</PMID>
  </reference>
  <results_reference>
    <citation>Leung JM, Sands LP, Rico M, Petersen KL, Rowbotham MC, Dahl JB, Ames C, Chou D, Weinstein P. Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients. Neurology. 2006 Oct 10;67(7):1251-3. Epub 2006 Aug 16.</citation>
    <PMID>16914695</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 19, 2005</study_first_submitted>
  <study_first_submitted_qc>September 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>February 5, 2019</results_first_submitted>
  <results_first_submitted_qc>August 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 10, 2020</results_first_posted>
  <last_update_submitted>August 25, 2020</last_update_submitted>
  <last_update_submitted_qc>August 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gabapentin</keyword>
  <keyword>pain</keyword>
  <keyword>surgery</keyword>
  <keyword>delirium</keyword>
  <keyword>cognitive decline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Plan to share undecided</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gabapentin</title>
          <description>Double blind, placebo controlled&#xD;
Gabapentin: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Double blind&#xD;
Gabapentin: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="374"/>
                <participants group_id="P2" count="376"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="350"/>
                <participants group_id="P2" count="347"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gabapentin</title>
          <description>Double blind, placebo controlled&#xD;
Gabapentin: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Double blind&#xD;
Gabapentin: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="350"/>
            <count group_id="B2" value="347"/>
            <count group_id="B3" value="697"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="350"/>
                    <measurement group_id="B2" value="347"/>
                    <measurement group_id="B3" value="697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" spread="6"/>
                    <measurement group_id="B2" value="72" spread="6"/>
                    <measurement group_id="B3" value="73" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="193"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="351"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="323"/>
                    <measurement group_id="B2" value="315"/>
                    <measurement group_id="B3" value="638"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="350"/>
                    <measurement group_id="B2" value="347"/>
                    <measurement group_id="B3" value="697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preoperative Cognitive Status as measured by Telephone Interview for Cognitive Status</title>
          <description>The Telephone Interview For Cognitive Status (TICS) is a standardized, 41-point measure of cognitive function. TICS has been developed and validated as an alternative to the Mini Mental State Examination (MMSE) but, unlike the latter, can be administered either in-person or by telephone. Higher scores means higher cognitive functioning. Lower scores means lower cognitive functioning.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.5" spread="3.5"/>
                    <measurement group_id="B2" value="34.5" spread="3.1"/>
                    <measurement group_id="B3" value="34.5" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Postoperative Delirium by Study Group</title>
        <description>Number of subjects who developed postoperative delirium, as measured by the Confusion Assessment Method, a validated tool for assessing delirium based on DSM-III-R, on any of the first three postoperative days.</description>
        <time_frame>postoperative days 1, 2 and 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Double blind, placebo controlled&#xD;
Gabapentin: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double blind&#xD;
Gabapentin: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Postoperative Delirium by Study Group</title>
          <description>Number of subjects who developed postoperative delirium, as measured by the Confusion Assessment Method, a validated tool for assessing delirium based on DSM-III-R, on any of the first three postoperative days.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="350"/>
                <count group_id="O2" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Postoperative Opioid Doses Across Study Follow up Period</title>
        <description>Postoperative intravenous opioid doses converted to morphine equivalents. Median derived from total opioid doses on first, second and third postoperative days.</description>
        <time_frame>Study follow up period: postoperative days 1, 2 and 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Double blind, placebo controlled&#xD;
Gabapentin: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double blind&#xD;
Gabapentin: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days</description>
          </group>
        </group_list>
        <measure>
          <title>Median Postoperative Opioid Doses Across Study Follow up Period</title>
          <description>Postoperative intravenous opioid doses converted to morphine equivalents. Median derived from total opioid doses on first, second and third postoperative days.</description>
          <units>morphine equivalents, mg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="350"/>
                <count group_id="O2" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="1.3" upper_limit="20"/>
                    <measurement group_id="O2" value="6.7" lower_limit="2.7" upper_limit="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Length of Stay</title>
        <time_frame>Typically within the first week after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Double blind, placebo controlled&#xD;
Gabapentin: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double blind&#xD;
Gabapentin: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="350"/>
                <count group_id="O2" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="3.4"/>
                    <measurement group_id="O2" value="4.1" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Pain Score - Postoperative Day 1</title>
        <description>Postoperative pain as measured by Visual Analog Pain scale (0=no pain, 10=worst pain imaginable).</description>
        <time_frame>Postoperative day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Double blind, placebo controlled&#xD;
Gabapentin: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double blind&#xD;
Gabapentin: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Pain Score - Postoperative Day 1</title>
          <description>Postoperative pain as measured by Visual Analog Pain scale (0=no pain, 10=worst pain imaginable).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="350"/>
                <count group_id="O2" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="3"/>
                    <measurement group_id="O2" value="4" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Pain Score - Postoperative Day 2</title>
        <description>Postoperative pain as measured by Visual Analog Pain scale (0=no pain, 10=worst pain imaginable).</description>
        <time_frame>Postoperative day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Double blind, placebo controlled&#xD;
Gabapentin: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double blind&#xD;
Gabapentin: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Pain Score - Postoperative Day 2</title>
          <description>Postoperative pain as measured by Visual Analog Pain scale (0=no pain, 10=worst pain imaginable).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="3"/>
                    <measurement group_id="O2" value="4" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Pain Score - Postoperative Day 3</title>
        <description>Postoperative pain as measured by Visual Analog Pain scale (0=no pain, 10=worst pain imaginable).</description>
        <time_frame>Postoperative day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Double blind, placebo controlled&#xD;
Gabapentin: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double blind&#xD;
Gabapentin: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Pain Score - Postoperative Day 3</title>
          <description>Postoperative pain as measured by Visual Analog Pain scale (0=no pain, 10=worst pain imaginable).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="3"/>
                    <measurement group_id="O2" value="3" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected over the time period of 1 year.</time_frame>
      <desc>In-hospital course was examined daily until discharge for occurrence of postoperative outcomes. All serious adverse events (both anticipated and unanticipated) were reported to the University of California San Francisco Committee on Human Research, and National Institutes of Health (San Francisco, California).</desc>
      <group_list>
        <group group_id="E1">
          <title>Gabapentin</title>
          <description>Double blind, placebo controlled&#xD;
Gabapentin: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Double blind&#xD;
Gabapentin: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="350"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="350"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Ventricular Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Heart Block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Unspecified Dysrhythmia</sub_title>
                <description>Charted as &quot;dysrhythmia&quot; or &quot;arrhythmia&quot;</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="350"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Sinus Tachy/Brady</sub_title>
                <description>Sinus tachycardia or bradycardia</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="350"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute Infection</sub_title>
                <description>As evidenced by positive lab cultures</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="350"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Esophageal Tear</sub_title>
                <description>&quot;Mallory-Weiss tear,&quot; nasogastric tube placed for 24 hours and tear resolved, advancing to regular diet.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <description>Anterior dislocation of left hip, closed reduction on floor without complication. Occurred twice on POD5 and POD7.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Renal Failure</sub_title>
                <description>Requiring new dialysis or acute increase in blood creatinine levels</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="350"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <description>Partial or complete collapse of part of or the entire lung</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia/Hypoxemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="350"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Pulmonary Edema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="350"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Reintubation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Reoperation</sub_title>
                <description>Requiring unscheduled second procedure within same hospital stay</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <description>Stroke or TIA shown by MRI</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="350"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sedation</sub_title>
                <description>Median sedation as defined as RASS score -2 (light sedation) or -3 (moderate sedation)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="350"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="347"/>
              </event>
              <event>
                <sub_title>Hallucinations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oxygen Desaturation</sub_title>
                <description>Oxygen desaturation below 95% but higher than 88%, as measured by pulse oximetry.</description>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="350"/>
                <counts group_id="E2" events="56" subjects_affected="56" subjects_at_risk="347"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Coordinator</name_or_title>
      <organization>University of California San Francisco</organization>
      <phone>4154769489</phone>
      <email>Christopher.Tang2@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

